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The toxigenic bacterium Vibrio cholerae belonging to the O1 and O139 serogroups is commonly associated with epidemic diar-
rhea in tropical settings; other diseases caused by this environmental pathogen are seldom identified. Here we report two unas-
sociated cases of nonfatal, nontoxigenic V. cholerae non-O1, non-O139 bacteremia in patients with comorbidities in Ho Chi
Minh City, Vietnam, that occurred within a 4-week period.
CASE REPORT
A63-year-old female patient was admitted to the Hospital forTropical Diseases (HTD) in Ho Chi Minh City (HCMC),
Vietnam, in June 2013. She recalled a 4-week history of fatigue
with loss of appetite, and she had developed jaundice with fever in
the week prior to admission. The patient had a history of hyper-
tension but no history of liver disease. On admission, she was fully
conscious, afebrile, and hemodynamically stable; her respiratory
rate was 20 breaths per minute. She had severe icterus, palmar
erythema, and peripheral edema, and her liver and spleen were not
palpable. She had detectable ascites (grade 2) but without abdom-
inal tenderness or portal vein thrombosis. The patient’s initial
laboratory results are shown in Table 1, and her viral hepatitis
serology results were as follows: anti-hepatitis A virus (anti-HAV)
(IgM), negative; anti-hepatitis B virus (anti-HBV), negative; anti-
HBc (IgM), negative; anti-hepatitis C virus (anti-HCV), negative;
and HBsAg, positive. She had a quantitative HBV PCR blood re-
sult of 1106 copies/ml (Abbott Real-time HBV kit). The initially
prescribed treatments were entecavir (0.5 mg once a day), rabe-
prazol (20 mg twice a day), diphenyl dimethyl bicarboxylate
(DDB) (25 mg thrice a day), furosemide (25 mg once a day), and
losartan (50 mg once a day). On the third day of admission, the
patient’s temperature peaked at 40°C with associated chills, nau-
sea, and dizziness but without diarrhea or abdominal pain. Her
procalcitonin level was elevated at 0.72 ng/ml. A bacterial infec-
tion was suspected, and 2 g/day of intravenous ceftriaxone was
added to the medications.
An aerobic BacT/Alert bottle was used for a blood culture and
incubated in a Bactec 9240 system (Becton Dickinson). The con-
tents of the incubated bottle became positive after 12 h. A Gram
stain on the positive BacT/Alert bottle revealed small curved
Gram-negative bacilli, which were subcultured onto blood and
MacConkey agar plates. The colonies displayed hemolysis on the
blood agar plates and were oxidase positive. API20E and VITEK2
identification (bioMérieux, France) confirmed the organism to be
Vibrio cholerae. Results of slide agglutination tests performed with
polyvalent O1 and O139 antisera were negative. Antimicrobial
susceptibility testing was performed by disc diffusion, and the
results were interpreted according to the Clinical and Laboratory
Standards Institute (CLSI) guidelines (1). The isolate was resistant
to trimethoprim-sulfamethoxazole and tetracycline and suscepti-
ble to chloramphenicol, ofloxacin, ciprofloxacin, azithromycin,
and ceftriaxone. The patient became afebrile after 2 days of ceftri-
axone treatment, and yet the antimicrobial therapy was contin-
ued, with the other treatments, for an additional 8 days. The pa-
tient was ultimately discharged after 24 days of hospitalization.
In July 2013, a 73-year-old man was admitted to HTD with
fever and confusion. He had been diagnosed with severe cirrhosis
due to hepatitis C infection in a private health care facility 4 years
previously and was actively receiving an unspecified treatment
regimen. He had been unwell for 4 days with fever and constipa-
tion. Initial examination on the day of admission to hospital re-
vealed the man to be thin, pale, and icteric, with peripheral edema
and spider angiomata. His pulse was 97 bpm, his blood pressure
was 140/80 mm Hg, and his respiratory rate was 24 breaths per
minute. He was febrile, with a temperature of 39°C. His mental
state was confused, and he was somnolent and had amnesia. A
chest X-ray suggested that the patient had pneumonia, and an
abdominal examination showed marked ascites with tenderness.
An abdominal ultrasound revealed large amount of ascitic fluid
and splenomegaly. A bacterial infection was suspected; therefore,
the patient was prescribed 2 g of intravenous ceftriaxone/day,
along with metronidazole (250 mg/day), furosemide (25 mg/day),
and lactulose.
A yellow sample of ascitic fluid was drawn which was Rivalta
test negative and negative for bacteria by Gram staining on mi-
croscopy. The fluid had 629 leukocytes/mm3 (86% neutrophils
and 14% lymphocytes), 1,000 erythrocytes/mm3, 9 g/liter of pro-
tein, and 5.8 g/liter of albumin. The ascitic fluid was cultured on
blood agar and MacConkey agar, and an aerobic BacT/Alert tube
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was taken for blood culture. Gram-negative curved bacilli were
found both in the blood and the ascitic fluid isolated after over-
night incubation. The organism in both samples was identified as
V. cholerae, and neither sample agglutinated with O1 and O139
antisera. Antimicrobial susceptibility testing demonstrated that
the organism was susceptible to all tested antimicrobials (ampicil-
lin, chloramphenicol, ciprofloxacin, ceftriaxone, ofloxacin, tri-
methoprim-sulfamethoxazole, and tetracycline). The patient be-
came afebrile after 2 days of ceftriaxone but was transferred to
another hospital for surgical intervention after being diagnosed
with bleeding of the upper gastrointestinal tract.
For confirmation of the microbiological identification, DNA
preparations from the isolates from both patients were subjected
to established PCR amplification methods targeting the rRNA in-
tergenic spacer region of V. cholerae (2), the cholera toxin (CT)
ctxA gene, the O1 O-antigen, and the O139 O-antigen (3). A tox-
igenic V. cholerae strain previously cultured from stool of a diar-
rheal patient was used as a control for the assays. All three of the
isolates (two from blood and one from ascitic fluid) were PCR
amplification positive for the rRNA intergenic spacer, confirming
their microbiological identification as V. cholerae. All of the iso-
lates were PCR amplification negative for the O139 antigen, the
O1 antigen, and the ctxA toxin gene. We hence concluded the
isolates to be nontoxigenic, non-O1, non-O139 V. cholerae.
Here we report two nonfatal cases of bacteremia caused by
nontoxigenic V. cholerae, an atypical manifestation of this some-
time pathogenic aquatic bacterial species. There are over 200 dif-
ferent reported serogroups of V. cholerae (4), but not all are capa-
ble of causing cholera. In fact, only CT-producing V. cholerae
strains belonging to the serogroups O1 and O139 are associated
with epidemic cholera (5, 6). However, other serogroups usually
referred as non-O1 and non-O139 strains are occasionally re-
ported to cause systematic infections. Patients with chronic syn-
dromes, such as cirrhosis, hematologic abnormalities, renal dial-
ysis, organ transplants, and immunosuppression, appear to be at
increased risk of V. cholerae non-O1, non-O139 infections (7–11).
Previous reports of retrospective studies originating from Taiwan
(7) and Thailand (12) have described patients with cirrhosis and
nontoxigenic Vibrio cholerae non-O1, non-O139 septicemia.
Spontaneous peritonitis has also been observed in patients with
Vibrio cholerae non-O1, non-O139 septicemia (13). The more
typical manifestations of this infection are ascites, fever, jaundice,
diarrhea, skin lesions, and gastrointestinal bleeding (13, 14), and
we observed the majority of these symptoms in the patients de-
scribed in this report. However, we observed no skin lesions or
cellulitis. It has been reported that non-O1, non-O139 V. cholerae
infections are associated with consumption of, or contact with,
raw seafood, which is a risk factor similar to that for the related
Vibrio speciesV. parahaemolyticus (15). However, is also notewor-
thy that neither of the patients whose cases are described here
reported contact with, or consumption of, seafood.
The management of Vibrio cholerae non-O1, non-O139 infec-
tions differs substantially from management of epidemic diarrhea.
The role of antimicrobials in severe cholera is not as critical as that
of fluid and electrolyte replacement. In contrast, antimicrobials
are essential for the management of extragastrointestinal Vibrio
infections; however, there are currently no standard guidelines for
treating this disseminated infection. Therefore, assessing the anti-
microbial susceptibility pattern of the infecting Vibrio sp. is para-
mount for tailoring treatment. Currently, Vibrio cholerae non-O1,
non-O139 isolates from many locations are still reported to be
susceptible to beta lactams, fluoroquinolones, trimethoprim-sul-
famethoxazole, tetracycline, and chloramphenicol (1, 3, 8, 9, 10).
It has been suggested that third-generation cephalosporins or
fluoroquinolones are the most suitable agents for treating V. chol-
erae septicemia (1). Indeed, ciprofloxacin seems to be associated
with a favorable outcome, and we can report here that both pa-
tients described in this report recovered from the bloodstream
infection quickly with a good clinical response after ceftriaxone
treatment.
This is the first report of nontoxigenicV. cholerae bacteremia in
Vietnam, a country in which the prevalence of hepatitis B virus
infection is high. This high prevalence of hepatitis in Vietnam
predicts increasing numbers of nontoxigenic V. cholerae infec-
tions in the future. We suggest that clinicians should consider
these organisms alongside the more common agents of bactere-
mia in diagnoses of cirrhosis patients in tropical settings.
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